1. Home
  2. SOLS vs ABVX Comparison

SOLS vs ABVX Comparison

Compare SOLS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SOLS

Solstice Advanced Materials Inc.

N/A

Current Price

$52.26

Market Cap

7.9B

Sector

Industrials

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$114.15

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOLS
ABVX
Founded
2025
2013
Country
United States
France
Employees
N/A
N/A
Industry
Aerospace
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
9.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOLS
ABVX
Price
$52.26
$114.15
Analyst Decision
Buy
Strong Buy
Analyst Count
3
12
Target Price
$54.00
$118.33
AVG Volume (30 Days)
3.8M
1.9M
Earning Date
02-11-2026
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.07
N/A
Revenue
$3,812,000,000.00
$6,231,374.00
Revenue This Year
$3.34
$6.80
Revenue Next Year
$3.67
N/A
P/E Ratio
$25.08
N/A
Revenue Growth
4.47
N/A
52 Week Low
$40.43
$4.77
52 Week High
$61.00
$148.83

Technical Indicators

Market Signals
Indicator
SOLS
ABVX
Relative Strength Index (RSI) N/A 43.25
Support Level N/A $116.20
Resistance Level N/A $129.56
Average True Range (ATR) 0.00 7.87
MACD 0.00 -2.47
Stochastic Oscillator 0.00 15.05

Price Performance

Historical Comparison
SOLS
ABVX

About SOLS Solstice Advanced Materials Inc.

Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: